XOMA Royalty (NASDAQ:XOMA) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?

XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $24.24 and traded as high as $25.93. XOMA Royalty shares last traded at $25.83, with a volume of 13,297 shares traded.

Analyst Ratings Changes

XOMA has been the subject of several recent research reports. Wall Street Zen raised shares of XOMA Royalty from a "hold" rating to a "buy" rating in a research report on Saturday. HC Wainwright reiterated a "buy" rating and issued a $104.00 price objective on shares of XOMA Royalty in a research note on Wednesday, May 28th. Finally, Benchmark started coverage on shares of XOMA Royalty in a research note on Thursday, April 17th. They issued a "buy" rating and a $35.00 price objective for the company.

XOMA Royalty Stock Performance

The company has a debt-to-equity ratio of 1.18, a quick ratio of 5.54 and a current ratio of 5.54. The stock has a market cap of $309.19 million, a PE ratio of -22.46 and a beta of 0.93. The company's 50 day simple moving average is $25.73 and its 200 day simple moving average is $24.24.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.32. The firm had revenue of $15.91 million during the quarter, compared to analyst estimates of $6.75 million. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. Analysts expect that XOMA Royalty Corporation will post -1.41 earnings per share for the current year.

Insider Activity at XOMA Royalty

In other news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the completion of the sale, the insider owned 1,267,545 shares in the company, valued at $34,350,469.50. This trade represents a 23.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Owen Hughes sold 25,637 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total transaction of $650,667.06. Following the sale, the chief executive officer owned 62,701 shares of the company's stock, valued at approximately $1,591,351.38. The trade was a 29.02% decrease in their position. The disclosure for this sale can be found here. Company insiders own 9.10% of the company's stock.

Institutional Investors Weigh In On XOMA Royalty

Several large investors have recently modified their holdings of the stock. Woodline Partners LP increased its stake in shares of XOMA Royalty by 7.9% during the 1st quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company's stock worth $3,359,000 after purchasing an additional 12,284 shares during the last quarter. Stonepine Capital Management LLC increased its stake in shares of XOMA Royalty by 3.3% during the 1st quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company's stock worth $2,587,000 after purchasing an additional 4,113 shares during the last quarter. Eversept Partners LP lifted its stake in shares of XOMA Royalty by 1.2% during the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock valued at $2,508,000 after buying an additional 1,128 shares in the last quarter. Northern Trust Corp lifted its stake in shares of XOMA Royalty by 1.5% during the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock valued at $2,396,000 after buying an additional 1,340 shares in the last quarter. Finally, CM Management LLC lifted its stake in shares of XOMA Royalty by 16.4% during the 1st quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock valued at $1,276,000 after buying an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.